Vimarsana
Biggest News Aggregation in the World

Page 7 - Multiple Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Myeloma Program Today - Breaking & Trending Today

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

Published: August 27, 2022

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm

Source: wiredprnews.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 27, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Source: prnewswire.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 27, 2022

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen P...

Source: businessinsider.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Vimarsana News

U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Published: December 1, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...

Source: prnewswire.com
Related Topics:
United StatesCraig TendlerJennifer McintyreChristie CorbettMyeloma ProgramJanssen Biotech IncMount Sinai Cancer Clinical Trials OfficeJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyDiagnostics Medical AffairsClinical ResearchGlobal Head Of Late DevelopmentAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationExchange CommissionCompanies Of JohnsonAmgen IncAnnual MeetingAjai ChariMultiple Myeloma ProgramAssociate Director
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Vimarsana News

U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Published: December 1, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...

Source: prnewswire.com
Related Topics:
United StatesCraig TendlerJennifer McintyreChristie CorbettMyeloma ProgramJanssen Biotech IncMount Sinai Cancer Clinical Trials OfficeJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyDiagnostics Medical AffairsClinical ResearchGlobal Head Of Late DevelopmentAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationExchange CommissionCompanies Of JohnsonAmgen IncAnnual MeetingAjai ChariMultiple Myeloma ProgramAssociate Director